Advisors Asset Management Inc. Has $13.75 Million Stock Position in AbbVie Inc. $ABBV

Advisors Asset Management Inc. cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 74,091 shares of the company’s stock after selling 2,840 shares during the period. Advisors Asset Management Inc.’s holdings in AbbVie were worth $13,753,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the second quarter worth $25,000. TD Capital Management LLC grew its position in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the 2nd quarter worth about $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $36,000. Finally, Bear Mountain Capital Inc. raised its holdings in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABBV has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price target on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average price target of $241.85.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $229.61 on Tuesday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company’s 50 day moving average price is $227.05 and its two-hundred day moving average price is $205.78. The firm has a market cap of $405.81 billion, a PE ratio of 109.34, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.